Reinach, 31 March 2020 – Evolva (SIX:EVE), the Swiss biotech company, today announced that the Standby Equity Distribution Agreement (SEDA) entered into in 2017 with Yorkville Advisors will expire on April 1, 2020.
Evolva is a Swiss biotech company focused on the research, development and commercialization of products based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at www.evolva.com.
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
# # #
Head of Investor and Corporate Relations
+ 41 61 485 2003 (direct)
+ 41 79 739 2636 (mobile)